



PATENT
Customer Number 22,852
Attorney Docket No. 6832.0062

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Craig A. Rosen, et al.) Group Art Unit: 1653
Application No.: 10/775,204)
Filed: February 11, 2004) Examiner: R. Wax
For: ALBUMIN FUSION PROTEINS)
COMPRISING GLP-1) Confirmation No.: 1797
POLYPEPTIDES)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), applicants bring to the attention of the Examiner the documents listed on the attached PTO/SB/08 form. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Information Disclosure Statement is accompanied by a fee of \$180.00 as specified by Section 1.17(p).

Copies of the listed foreign and non-patent literature documents are attached.

Copies of the U.S. patent publications are not enclosed.

04/27/2005 HALI11 00000118 10775204

05 FC:1806

180.00 0P

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached forms.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: April 26, 2005

By: Lucia C. Kelley Reg# 41,551
Charles E. Van Horn
Reg. No. 40,266


INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	6832.0062-00
-------	---	----	---	------------------------	--------------

Complete if Known

Application Number	10/775,204
Filing Date	February 11, 2004
First Named Inventor	Craig A. Rosen et al.
Art Unit	1653
Examiner Name	Robert Wax



U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US 5,545,618	08/13/96	Buckley et al.	
		U.S. 5,646,012	07/08/1997	Fleer et al.	
		U.S. 5,876,969	03/02/1999	Fleer et al.	
		U.S. 6,514,500	02/04/2003	Bridon et al.	
		U.S. 6,686,179	02/03/2004	Fleer et al.	
		U.S. 5,612,196	03/18/1997	Becquart et al.	
		U.S. 6,165,470	12/26/2000	Becquart et al.	
		U.S. 5,766,883	6/16/1998	Ballance, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		WO 05/000892	01/06/05	Eli Lilly and Company		
		WO 02/46227	6/13/2002	Eli Lilly and Company		
		WO 03/059934	7/24/2003	Human Genome Sciences, Inc.		
		WO 01/77137	10/18/01	Human Genome Sciences, Inc.		
		EP 0 624 195	11/17/94	Rhone Poulenc Rorer SA		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
		ADELHORST, K. et al., "Structure-Activity studies of glucagon-like peptide-1," J. Biol. Chem. 269 (9): 6275-6278 (1994).	
		GALLWITZ, B. et al., "Structure/activity characterization of glucagon-like peptide-1," Eur. J. Biochem. 225: 1151-1156 (1994).	
		HJORTH, S.A. et al., "Glucagon and glucagons-like peptide-1: selective receptor recognition via distinct peptide epitopes," J. Biol. Chem. 269 (48): 30121-30124 (1994).	
		ORSKOV, C. et al., "Complete sequences of glucagons-like peptide-1 from human and pig small intestine," J. Biol. Chem. 264 (22): 12826-12829 (1989).	
		PARKER, J.C. et al., "Structure-function analysis of a series of glucagons-like peptide-1 analogs," J. Peptide Res. 52: 398-409 (1998).	
		URSO, B. et al., "Differences in signaling properties of the cytoplasmic domains of the insulin receptor and insulin-like growth factor receptor in 3T3-L1 adipocytes," J. Biol. Chem. 274(43): 30864-30873 (1999).	
		European Search Report for Appln. No. 02799966.3-1212-US024891, Jan. 20, 2005	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.